1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nutex Health said an unauthorized third party has published on its website data allegedly obtained in the previously disclosed cyber security event. The company said it has not identified any material impact on its business operations or financial reporting systems so far, and that its materiality assessment is unchanged, but it cannot yet estimate the event's impact on its results or stock price.
Unauthorized party published data allegedly obtained in the cyber event on its website; the company is reviewing contents, scope and authenticity, a process expected to take several weeks
No material impact on business operations or financial reporting identified to date; materiality assessment from the August 31, 2026 Form 8-K unchanged
Several purported class action complaints filed in the U.S. District Court for the Southern District of Texas, Houston Division, after the initial August 24, 2026 disclosure
Company says it cannot predict litigation outcome or estimate impact on operations, financial condition or stock price
Circle8 Group confirmed it has submitted a preliminary, non-binding and highly indicative proposal for a possible cash offer for SThree plc, a London-listed specialist STEM business. The company says the deal is structured to be financed without issuing new Circle8 common stock, so existing shareholders would not be diluted, but it also states there is no certainty that a firm offer will be made.
Proposal is preliminary, non-binding and highly indicative; no firm offer has been made
Company says the transaction is structured to be financed without issuing additional Circle8 common stock
SThree generated approximately £1.3 billion in gross revenue in fiscal 2025; combined gross revenues could approach $3 billion
Circle8 generated more than $1.2 billion in gross revenue during 2025
ARC Group Acquisition I Corp, a special purpose acquisition company, signed a share purchase agreement to acquire all shares of Malaysian private financing company Firstborn Top Capital Sdn. Bhd. The base consideration is $1.0 billion, adjusted for net indebtedness, working capital and transaction bonuses, and is paid in Class A shares of the SPAC, which will be renamed BlueCrest Investment, Inc. Closing requires shareholder approval and is expected in the first quarter of 2027, and existing ARCL shareholders may redeem their shares for trust funds before the vote.
Base consideration of $1.0 billion, before adjustments for closing net indebtedness, working capital and unpaid transaction bonuses
Implied pro forma enterprise value at closing of approximately $1,091.2 million, assuming $5 million of PIPE financing and 0% redemption from the $120.8 million trust account
Expected post-closing ownership: about 12.4% held by public investors and about 82.39% by existing Firstborn shareholders
Either party may terminate if closing has not occurred by January 31, 2027, subject to extension; expected closing in the first quarter of 2027
Copart agreed to acquire ACV Auctions through a cash tender offer at $10.50 per share, an implied equity value of about $1.9 billion, followed by a merger. The price is a premium of about 45% to ACV's unaffected closing price on August 10, 2026, and about 41% to its 30-day volume-weighted average price. For Copart shareholders, the company expects the deal to be neutral to earnings per share in the first full year of ownership and accretive in fiscal 2028 and beyond.
Offer price of $10.50 per share in cash, implied equity value of about $1.9 billion
Premium of about 45% to ACV's unaffected closing price on August 10, 2026
Termination fee of $57.7 million payable by ACV; $115.3 million payable by Copart under specified circumstances
Expected to close by calendar year-end 2026, funded with cash on hand; not subject to a financing condition
iSpecimen received a Nasdaq letter dated September 8, 2026, granting an extension until November 25, 2026 to regain compliance with the minimum stockholders' equity requirement. The company says it plans a best-efforts public offering of approximately $5 million in gross proceeds, but the filing states there is no assurance it will regain or maintain compliance, and shareholders could face delisting if it fails to do so.
Nasdaq first notified the company of noncompliance on May 29, 2026, under Listing Rule 5550(b), which requires at least $2,500,000 in stockholders' equity.
The company cites a private placement that closed May 11, 2026, with gross proceeds of approximately $2.5 million, and a planned public offering of approximately $5 million.
Projections show stockholders' equity of approximately $5.1 million through June 30, 2027, per the filing.
The Deficiency Letter has no immediate effect on trading of the common stock on the Nasdaq Capital Market.
Ameresco's board named two finance vice presidents to serve as interim principal financial officer and interim principal accounting officer while the company searches for a new chief financial officer. CFO Mark Chiplock, who resigned as previously disclosed in an August 19, 2026 filing, leaves the role effective September 25, 2026.
Julie Bradshaw, Vice President, Finance, designated interim principal financial officer on September 8, 2026
Debbie Angelico, Vice President, Finance, designated interim principal accounting officer on September 8, 2026
Mark Chiplock's resignation as CFO and principal financial and accounting officer is effective September 25, 2026
The company has commenced a search for a new Chief Financial Officer
Kadant's board adopted a succession plan under which Michael C. Colwell becomes president and chief operating officer on October 1, 2026, and president and chief executive officer on January 2, 2027, when Jeffrey L. Powell becomes executive chairman. Chairman Jonathan W. Painter will leave the board on January 2, 2027. The filing contains no financial results, and the changes are a planned leadership transition for shareholders to track.
Michael C. Colwell, 60, is senior vice president responsible for the Industrial Processing segment and will join the board on January 2, 2027.
Jeffrey L. Powell remains president through September 30, 2026, and CEO through January 2, 2027, then becomes executive chairman and retires January 1, 2028.
Powell's annualized base salary will be $998,900 through January 2, 2027, and $499,450 after that, under a Transition and Executive Chairman Agreement.
Jonathan W. Painter, current chairman, will cease to serve as a director on January 2, 2027; he stated his resignation did not result from any disagreement with the Company.
TransMedics appointed Fernando Araujo, most recently CFO of GE HealthCare's Advanced Imaging Solutions segment, as Chief Financial Officer and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez, who will move to a non-executive role and then a senior advisor position focused on Latin America. In the same announcement, the company reiterated its 2026 revenue guidance of $737 million to $757 million, which excludes PAD Aviation and will be revisited with third quarter results. The filing reports no change to financial results or guidance, but the change in finance leadership is a notable item for shareholders.
Fernando Araujo, age 46, becomes CFO and Treasurer effective September 21, 2026, with a $590,000 base salary and a 60% target bonus
Araujo receives a $200,000 cash sign-on bonus plus initial stock option and RSU awards each with a grant date value of approximately $1.75 million
Gerardo Hernandez remains a non-executive employee through December 31, 2026, then serves as a non-employee senior advisor until April 30, 2027
2026 revenue guidance of $737 million to $757 million was reiterated; the company will revisit it with third quarter 2026 results
GGeoVax Labs said it has requested a Nasdaq Hearings Panel appeal of a delisting determination it received on August 27, 2026, over the minimum bid price requirement, with a hearing scheduled for October 13, 2026. The company says its stock should keep trading on the Nasdaq Capital Market under GOVX at least through that period, and it reaffirmed its focus on the GEO-MVA vaccine program and Gedeptin.
Nasdaq delisting determination received August 27, 2026, relating to the minimum bid price requirement under Listing Rule 5550(a)(2)
Hearing before the Nasdaq Hearings Panel scheduled for October 13, 2026
Hearing request has stayed any suspension or delisting action; GOVX expected to keep trading at least through that period
GeoVax plans to present a compliance plan to regain and maintain listing standards
CVD Equipment Corporation said its board committed to a restructuring plan that ends new system orders for its CVD equipment business and cuts the workforce by about half, keeping only what is needed for its remaining backlog, warranties, and spare parts, quartz, and services. The company expects a restructuring charge of $0.8 million to $1.0 million in the quarter ending September 30, 2026, and CEO Emmanuel Lakios has left the company and the board, with Vice President of Manufacturing Operations Warren Cheesman named Acting CEO.
Restructuring charge expected at approximately $0.8 million to $1.0 million in the quarter ending September 30, 2026, mainly employee severance
Company will no longer pursue new system orders for its CVD equipment business and will cut its workforce by approximately half
Emmanuel Lakios departed as President and CEO and from the board effective September 3, 2026; Warren Cheesman is Acting CEO
At the end of the second quarter of 2026, the company had $23.5 million in cash and no debt
Oracle reported fiscal first-quarter 2027 results for the quarter ended August 31, 2026, with revenue up 30% to $19.3 billion and diluted GAAP EPS up 55% to $1.56. The company also gave Q2 and full fiscal 2027 guidance, including total revenue of at least $90 billion, and declared dividends. Free cash flow was negative $5.4 billion as capital expenditures reached $28.5 billion, a figure shareholders will watch alongside the growth in cloud revenue.
Total revenue $19.3 billion, up 30%; cloud revenue $11.6 billion, up 62%; cloud infrastructure $7.4 billion, up 121%
Diluted GAAP EPS $1.56, up 55%; non-GAAP EPS $1.92, up 30%
Operating cash flow $23.1 billion, but free cash flow was negative $5.4 billion
Common dividend $0.50 per share payable October 23, 2026 (record date October 9); preferred dividend $1,625 per share payable October 15, 2026
20/20 Biolabs, Inc. (AIDX) received a Nasdaq notice on September 3, 2026 saying it does not meet the $2,500,000 stockholders' equity requirement, based on its Form 10-Q showing $1,620,700 at June 30, 2026. The company has 45 calendar days to submit a compliance plan, and failing to regain compliance could bar it from the extra time it would otherwise get on the bid price issue, adding delisting risk for shareholders.
September 3, 2026: Nasdaq notice citing stockholders' equity of $1,620,700 versus a $2,500,000 requirement
Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 more days if accepted
Separate July 17, 2026 notice on the $1.00 bid price rule; compliance deadline is January 13, 2027
Missing the equity rule by January 13, 2027 would disqualify the company from a second bid price compliance period
Frequency Electronics reported first-quarter fiscal 2027 results for the quarter ended July 31, 2026, with revenue of $23.5 million, up from $13.8 million a year earlier. Net income rose to $4.2 million, or $0.41 per diluted share, from $0.07 a year earlier, and the company said a secondary offering added approximately $73 million in cash.
Revenue was approximately $23.5 million, up 70% from $13.8 million in the same quarter of fiscal 2026.
Operating income was $5.2 million, compared with $0.4 million a year earlier.
Net income was $4.2 million, or $0.41 per diluted share, versus $0.07 per diluted share a year earlier.
Funded backlog was approximately $129 million at July 31, 2026, up from $111 million at April 30, 2026.
Adobe reported third quarter fiscal 2026 results for the quarter ended August 28, 2026, with revenue of $6.76 billion, up 13% year over year, and non-GAAP diluted earnings per share of $6.13, up from $5.31 a year earlier. The company also raised its full-year fiscal 2026 revenue and earnings per share targets, which matters to shareholders because it signals higher expected profit for the year.
Q3 FY2026 revenue was $6.76 billion, up 13% year over year (12% in constant currency).
Diluted EPS was $4.62 on a GAAP basis (vs. $4.18) and $6.13 on a non-GAAP basis (vs. $5.31).
FY2026 revenue target is now $26.576 billion to $26.626 billion; non-GAAP EPS target is $24.45 to $24.50.
Q4 FY2026 revenue target is $6.80 billion to $6.85 billion; Q3 share repurchases were about 9.5 million shares.
DigitalOcean and its subsidiary entered into a $725 million equipment finance facility with MUFG entities to fund data center equipment, with an accordion feature that could raise total commitments to $1.025 billion. The company says it intends to exercise the accordion in full, subject to new or existing lenders committing, and the facility is guaranteed by the parent and certain subsidiaries and secured by the equipment. The new debt-like obligation carries fixed rates tied to term SOFR swaps plus 2.75% and financial covenants, and the CFO said the company remains highly confident in its 2026 guidance.
Committed financing of up to $725 million; advances can fund up to 90% of equipment cost, with the balance paid as prepaid rent
Accordion can add up to $300 million, for up to $1.025 billion in total, subject to lender commitments
Advances available until September 10, 2027; rent amortizes each advance in full by September 10, 2030
Each advance bears a fixed rate equal to term SOFR swap rate plus 2.75%; undrawn commitment fee of 0.20% rising to 0.40% six months after closing
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, paying $270 million in cash and issuing 2,908,692 shares at closing. Alkeus shareholders may also receive up to $350 million in milestone payments tied to regulatory approval and first U.S. sales, plus revenue-sharing payments on future gildeuretinol sales. The filing does not provide financial results for Alkeus, so its effect on Tarsus's financials is not yet quantified.
Acquisition closed September 4, 2026, with Alkeus becoming a wholly-owned subsidiary of Tarsus
Up-front consideration: $270,000,000 in cash, subject to adjustments, plus 2,908,692 shares of common stock
Milestones up to $350 million: $250 million on U.S. regulatory approval of an Alkeus product, and $100 million in cash on first U.S. sale
Financial statements and pro forma information will be filed by amendment within 71 calendar days
Central Plains Bancshares, Inc. said its Board of Directors approved a new stock repurchase program on September 9, 2026, under which it may buy back up to 417,481 shares, approximately 10% of current outstanding shares. The new program replaces the company's current repurchase program. The filing does not state a timing or funding for repurchases.
Board approved the new repurchase program on September 9, 2026
Program covers up to 417,481 shares, approximately 10% of current outstanding shares
New program replaces the company's current repurchase program
Announced in press release dated September 9, 2026 (Exhibit 99.1)
SKYX Platforms signed a merger agreement on September 9, 2026, under which Deako, a Seattle-based AI smart home and lighting systems company, will become a wholly owned subsidiary. SKYX will issue 25,000,000 shares, or 18.46% of its outstanding common stock, plus $4 million in cash and $8.5 million in senior secured notes to Deako's senior lenders, and closing requires Deako securityholder approval. The filing does not include SKYX or Deako financial results beyond a press release statement that Deako had over $26 million in 2025 revenue, so shareholders face dilution and new debt without a stated effect on SKYX's profit.
Consideration: 25,000,000 common shares (18.46% of outstanding), with a 12-month lock-up and releases of 25% each at 12, 15, 18 and 21 months after closing, held in escrow for Deako's senior lenders.
Cash: $4 million total, of which $2 million was paid at signing and $2 million is due at closing.
Notes: $8.5 million senior secured promissory notes at 12.0% per annum; $2.25 million due 120 days after closing and the remainder due on the 12-month anniversary of closing.
Termination right if closing conditions are not met or waived by October 31, 2026; closing also requires Deako securityholder approval.
Versus Systems appointed Brian Goldenberg as its Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer on September 8, 2026. CEO Luis Goldner will no longer serve as principal financial officer, so the CFO role now sits with Goldenberg, who previously held CFO positions at Trend Capital Management and Divisadero Street Capital Management.
Brian Goldenberg appointed CFO, principal financial officer and principal accounting officer on September 8, 2026
Luis Goldner, President and CEO, will no longer serve as principal financial officer
Goldenberg was CFO of Trend Capital Management, Boca Raton, Florida, from February 2018 to November 2023
From November 2023 to February 2026, Goldenberg was COO, chief compliance officer and CFO of Divisadero Street Capital Management, Miami, Florida
On September 10, 2026, Commerce.com (Nasdaq: CMRC) announced a strategic operating plan to reduce costs, along with its Board's authorization of up to $50 million in share repurchases through September 10, 2028. The company raised its full-year 2026 non-GAAP operating income guidance by $3 million and reaffirmed its revenue guidance, but it expects restructuring charges of $8.5 million to $26.3 million across the third and fourth quarters of 2026.
The plan is expected to generate annualized cost savings of $60 million to $80 million, or $0.73 to $0.97 per diluted share, with about $3 million realized in 2026.
Restructuring and one-time expenses are estimated at $4.2 million to $8.8 million in the quarter ending September 30, 2026, and $4.3 million to $17.5 million in the fourth quarter of 2026.
Full-year 2026 non-GAAP operating income guidance was raised to $31.0 million to $37.0 million from $28.0 million to $34.0 million; revenue guidance was reaffirmed at $336.5 million to $344.5 million.
The Board authorized repurchases of up to $50 million of common stock, to be funded from available cash, with no obligation to buy any specific amount.
SCYNEXIS said Chief Financial Officer Ivor Macleod retired effective September 9, 2026, and named Sanjay Subramanian as his successor, with an employment agreement effective the same day. Macleod will stay with the company through October 9, 2026 to support the transition. The filing contains no financial results or guidance, so the change is a leadership update rather than a measure of company performance.
Ivor Macleod ceased serving as CFO, principal financial officer and principal accounting officer effective September 9, 2026, and remains with the company through October 9, 2026.
Sanjay Subramanian's employment agreement is effective September 9, 2026, with an annual base salary of $500,000 and a discretionary annual bonus of up to 40% of base salary.
Subramanian received a stock option for 100,000 shares at $4.91, the September 9, 2026 closing price, vesting over four years.
Severance is nine months' base salary if terminated outside 12 months after a change of control, and 18 months' base salary if within that period.
On September 4, 2026, Cerenome entered into a securities purchase agreement with an institutional investor for senior secured convertible notes with an aggregate original principal of $21,276,596, with an initial closing expected on or about September 10, 2026. The notes are secured by substantially all company and CNSide assets, carry 8.0% interest and a one-year maturity, and convert into common stock, and a royalty of 2.5% of CNSide gross revenues is expected to be paid to the investor, so the financing adds secured debt, a revenue-linked payment and potential share dilution for shareholders.
Aggregate original principal of $21,276,596, including $3,191,489 Initial Notes, $2,127,660 Second Notes and $15,957,447 Additional Notes.
Expected gross proceeds of $3,000,000 at the initial closing on or about September 10, 2026, before legal fees and transaction expenses.
Notes carry 8.0% interest and a 6.0% original issue discount, mature one year after issuance, and have an initial conversion price of $2.74 per share with a $0.50 floor.
Quarterly royalty of 2.5% of CNSide gross revenues, guaranteed by Cerenome, remains in effect until the notes are paid in full.
Huntington Bancshares appointed Brantley J. Standridge as President of the Company and its bank subsidiary, effective September 8, 2026, taking the role from Chairman and CEO Stephen D. Steinour, who remains in his current positions. The filing also raises Standridge's pay targets effective September 15, 2026.
Brantley J. Standridge, 50, appointed President effective September 8, 2026; he previously served as Senior Executive Vice President and President of Consumer and Regional Banking since April 2023
Stephen D. Steinour continues as Chairman and Chief Executive Officer of the Company and CEO of The Huntington National Bank
Base salary increases from $850,000 to $1,000,000; annual incentive target rises from $1,487,500 to $1,850,000, pro-rated for 2026; long-term incentive target rises from $2,762,500 to $4,650,000, effective September 15, 2026
Hanover Bancorp furnished an investor presentation under Regulation FD for presentation to investors on September 10, 2026. The slides show Q2 2026 net income of $4.1 million and diluted EPS of $0.55, up from $1.9 million and $0.25 in the first quarter of 2026. A footnote says a pending acquisition of Minden is subject to regulatory approvals and Minden shareholder approval, and the filing gives no further detail on it.
Q2 2026 net income was $4.1 million, versus $1.9 million in Q1 2026 and $2.4 million in Q2 2025.
Q2 2026 diluted EPS was $0.55, versus $0.25 in Q1 2026 and $0.33 a year earlier; adjusted diluted EPS was $0.58.
The Minden acquisition requires regulatory approvals and Minden shareholder approval; the private placement is not conditional on its closing.
Non-accrual loans were $28.3 million at June 30, 2026, or 1.42% of total loans.
Village Farms International appointed Hamid Shekarchi as Interim Chief Financial Officer effective September 10, 2026, replacing Stephen Ruffini in that role. The company states that Ruffini's transition is not the result of any disagreement with management or the board, and he remains Company Secretary and takes on the role of Head of M&A.
Hamid Shekarchi, 41, was CFO of the company's Canadian Cannabis operations since February 1, 2024, and joined the Pure Sunfarms subsidiary in 2021.
Stephen Ruffini ceases to serve as CFO as of September 10, 2026, but stays on as Company Secretary, Head of M&A, advisor to the CEO and a full-time employee.
Shekarchi's interim CFO pay includes a C$567,000 annual base salary, a 50% target bonus, a 100,000 stock option grant and a one-time RSU award of 20% of base salary.
If Shekarchi is terminated without cause, the company will provide 12 months' notice by lump sum or continuance.
On September 9, 2026, DuPont, Chemours and Corteva entered a settlement with the State of North Carolina and 11 local entities to resolve PFAS-related claims, including claims tied to the Fayetteville Works facility and AFFF-related contamination. The settlement is subject to entry of orders dismissing the covered claims, and DuPont recorded a probable loss of about $125 million in the second quarter of 2026, which the press release says is materially covered by existing accruals.
Aggregate cash payment of $455 million to the plaintiffs, payable over 15 years, shared under the 2021 MOU; $18 million is attributed to PFAS contamination unrelated to Fayetteville Works.
DuPont recorded a probable loss of about $125 million in Q2 2026 within discontinued operations, before Qnity Electronics' reimbursement of 44% of DuPont's share.
DuPont and Corteva will establish a $135 million Reserve Fund, accessible only if Chemours fails to perform under its 2019 Consent Order with the State.
Future MOU escrow contributions, including the one due in September 2026, will be considered satisfied by the New Jersey and North Carolina settlement payments.
EyePoint posted an updated investor presentation on September 10, 2026, with preliminary topline results from the LUGANO Phase 3 wet AMD trial of DURAVYU. The filing states DURAVYU did not achieve statistical non-inferiority to on-label aflibercept in the full data set, a miss on the primary endpoint, and the company attributes the result mainly to 9 patients who lost 15 or more letters of vision from non-wet AMD causes.
Full data set: DURAVYU did not achieve statistical non-inferiority on mean change in BCVA versus on-label aflibercept (preliminary, pending final analysis).
Excluding the 9 of 211 DURAVYU patients in the asymmetric cohort, non-inferiority was achieved (nominal p=0.0096).
LUCIA Phase 3 data are expected in Q4 2026, and a wet AMD NDA filing is targeted for 1H 2027.
The presentation is filed as Exhibit 99.1 and is incorporated by reference; all LUGANO data are labeled preliminary.
Vince Holding reported second quarter 2026 net sales of $81.8 million, up 11.7% from a year earlier, and raised its full-year fiscal 2026 outlook for the Vince business. GAAP net income fell to $10.6 million, or $0.80 per diluted share, from $12.1 million, or $0.93, a year earlier, because the prior-year quarter included a $5.6 million employee retention credit benefit. The company also completed its OVO acquisition, which it says is outside the outlook.
Net sales rose 11.7% to $81.8 million; wholesale up 10.4% to $49.4 million and direct-to-consumer up 13.7% to $32.4 million
GAAP diluted EPS was $0.80 vs. $0.93; adjusted diluted EPS was $1.02 vs. $0.38, including tariff refunds and excluding $2.9 million of OVO transaction costs
Fiscal 2026 outlook raised: Vince business net sales now expected to increase approximately 8% to 10%, excluding OVO
OVO acquisition completed, following the August 27, 2026 announcement; the company paid $6 million for a 5% stake in the OVO intellectual property holding entity
Fortrea's board reinstated Jason Knoblauch as Chief Financial Officer on September 9, 2026, after a temporary restraining order that had kept him from the role was resolved through a settlement and mutual release. Director David Smith, who had served as interim CFO during the leave, stepped down from that role but remains on the board.
Board reinstated Jason Knoblauch as CFO and principal financial officer on September 9, 2026
Delaware Court of Chancery had issued a temporary restraining order on July 25, 2026 barring him from working as CFO
Company, Knoblauch and his former employer entered a settlement agreement and mutual release
David Smith stepped down as interim CFO but remains a board member
Macy's reported second-quarter 2026 results for the 13 weeks ended August 1, 2026, with net sales up 1.1% to $4.9 billion and GAAP diluted EPS of $0.62, up from $0.31 a year earlier. The company raised its full-year 2026 guidance, including adjusted diluted EPS of $2.15 to $2.35, up from $2.00 to $2.20, and the quarter included a $0.23 per share net tariff refund benefit.
Net sales rose 1.1% to $4.9 billion; comparable sales rose 2.7%, and Bloomingdale's comparable sales rose 11.3%.
GAAP diluted EPS was $0.62 versus $0.31; adjusted diluted EPS was $0.63 versus $0.35, including a $0.23 net tariff refund benefit.
Full-year 2026 guidance now calls for net sales of $21.675 billion to $21.825 billion and comparable sales growth of 1.0% to 1.5%.
The board declared a quarterly dividend of 19.15 cents per share, payable October 1, 2026, to holders of record on September 15, 2026.
Designer Brands reported second-quarter 2026 results for the quarter ended August 1, 2026, with net sales down 1.2% to $730.6 million but net income attributable to the company rising to $17.6 million, or $0.31 per diluted share, from $10.5 million, or $0.21, a year earlier. The company raised its full-year 2026 adjusted diluted EPS guidance to $0.47-$0.52 from $0.28-$0.38, citing strong operating performance and a positive start to the third quarter.
Net sales fell 1.2% to $730.6 million; total comparable sales decreased 2.4%.
GAAP diluted EPS was $0.31 versus $0.21 last year; adjusted diluted EPS was $0.34 versus $0.33.
Full-year 2026 adjusted diluted EPS guidance raised to $0.47-$0.52 from $0.28-$0.38; net sales guidance raised to flat to up 1% from down 1% to up 1%.
Board approved a quarterly cash dividend of $0.05 per share, payable October 7, 2026 to holders of record on September 24, 2026.
Chemours, DuPont and Corteva agreed on September 9, 2026 to settle PFAS-related claims by the State of North Carolina and 11 local entities, including claims tied to the Fayetteville Works facility. Chemours will pay 50% of the $455 million settlement under the 2021 cost-sharing memorandum, and the company says its share is covered by existing accruals. The settlement remains subject to court orders dismissing the covered claims.
Total settlement payments are $455 million over 15 years, beginning within 30 days of the agreement's execution date.
Chemours' 50% share is approximately $180 million on a net present value basis, which the company says is covered by existing accruals.
Chemours expects to pay approximately $50 million over the next twelve months.
All future MOU escrow contributions are considered satisfied, including Chemours' $50 million contribution that would have been due in September 2026.
Shoe Station Group reported second-quarter results for the period ended August 1, 2026, with net sales of $284.3 million, down from $306.4 million a year earlier, and net income of $6.3 million, or $0.23 per diluted share, versus $0.70 in the prior-year quarter. The company lowered its fiscal 2026 net sales and adjusted EPS guidance, which matters to shareholders because the company cites a more promotional footwear market and weaker assortments as pressures that it expects to continue through the rest of the year.
Q2 2026 net sales were $284.3 million versus $306.4 million, with comparable store sales down 7.1 percent.
Gross profit margin was 31.9 percent versus 38.8 percent in Q2 2025; net income was $6.3 million, or $0.23 per diluted share, versus $0.70.
Fiscal 2026 guidance now calls for net sales of $1.100 billion to $1.111 billion, GAAP EPS of $0.32 to $0.47, and adjusted EPS of $0.75 to $0.90.
Comparable store sales declined 2.7 percent in the four weeks ended August 29, 2026, an improvement from the Q2 decline of 7.1 percent.
Swarmer, Inc (SWMR) signed an agreement on September 9, 2026 to buy 100% of Ukrainian unmanned ground vehicle maker Ratel Robotics, with consideration of cash and stock worth up to $224 million if all earnout milestones are met. The deal requires Swarmer stockholder approval because of the stock issuance and is expected to close in the fourth quarter of 2026, so shareholders face potential dilution and a deal that depends on earnout performance.
Estimated $7.2 million in cash and 1,064,942 common shares due at closing, with up to $7.2 million in cash and up to 4,422,125 additional shares tied to 2026 to 2028 revenue and Operating Income targets
Stockholder approval is required under Nasdaq Listing Rule 5635(a) before the stock can be issued
Closing is expected in the fourth quarter of 2026 and either party may terminate if it has not closed by January 7, 2027
Ratel Robotics has more than 300 employees and secured contracts totaling $86 million this year, according to the press release
Axogen agreed on September 9, 2026 to acquire BioCircuit Technologies for a base price of $200.0 million in cash, subject to customary adjustments, with closing expected in the fourth quarter of 2026. On September 10 it priced an offering of 4,910,000 common shares at $42.50 each, with gross proceeds of about $208.7 million before underwriting discounts and expenses, which it plans to use mainly to fund the purchase. Shareholders face new share issuance and the risk that the deal does not close on the expected timeline.
Merger: $200.0 million base cash price; $1.0 million withheld at closing for post-closing adjustments; either party may terminate if not completed by December 31, 2026; no termination fee.
Offering: 4,910,000 shares at $42.50 per share; underwriters pay $39.95 per share; a 30-day option covers up to 736,500 more shares; closing expected September 11, 2026.
Gross proceeds of about $208.7 million (before discounts and expenses, excluding the option); the offering is not conditioned on the merger closing.
BioCircuit's investor presentation cites about $24 million run-rate revenue (Q2 2026 annualized) and $11 million of 2025 revenue.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.